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We read with great interest a case report on the use of
etanercept in the management of refractory severe erythema
nodosum leprosum (ENL) [1]. We appreciate that the authors
managed the case successfully with this newer biologic.
Managing refractory ENL reactions is an important and diffi-
cult task because of the patient’s psychological stress, adverse
effects, and poor responses to antireaction drugs. We under-
stood this and have tried to clarify certain doubts regarding
the management and mechanisms of action. In the case
report it was mentioned that over 6 months, multiple
extended courses of higher doses of prednisolone, clofaz-
imine, thalidomide, minocycline, clarithromycin, ofloxacin,
pentoxifylline, and azathioprine were used and the patient
had few symptom-free periods and experienced many ENL-
related episodes with increased severity. We were surprised
regarding the use of multiple drugs within a short period of
6 months. The use of the antibiotics minocycline (bacterio-
static), ofloxacin, and clarithromycin (bactericidal) daily for
6 months along with multidrug therapy is not understandable
and is questionable as to whether they were used as addi-
tional antileprotic drugs or for necrotic ulcers to prevent sep-
sis. These drugs are used as an alternative or substitute in any
resistance or contraindicated cases only as per World Health
Organization protocol [2,3]. In the article it was mentioned
that after receiving etanercept for 12 weeks, the patient
improved significantly, allowing for a slow taper and eventual
discontinuation of prednisolone. This shows that the patient
response may be due to a combinational effect of etanercept
with prednisolone. The dosage of prednisolone at the start oftaking etanercept is important for knowing patient clinical
responses. As per World Health Organization protocol clofaz-
imine may be used for up to 12 months in the management of
severe ENL and the current usage in this particular case is not
mentioned. After a month of tapering/stoppage of steroids
the patient did not have any recurrence of ENL. The same
reaction-free interval has also been achieved in the past.
Therefore, we feel that there is a need for a longer follow-
up period before making a conclusion on the response by
etanercept alone. The patient had already completed seven
pulses of multidrug therapy with additional bactericidal drugs
for 6 months when the first dose of etanercept was given. By
this time, the morphological index might be 0 with a rare
reduction in bacterial index that might have contributed to
the reduced risk of recurrence of ENL and its severity. The
irrational use of additional drugs may trigger very severe
necrotic lesions. Minocycline has the property of causing
skin-related adverse effects [4]. The current status of this
patient is mandated as the first case report on etanercept
showing a single recurrence (treated with thalidomide for
3 months) with a 1-year reaction-free period of a patient
who was treated for 2 years and followed-up for 2.5 years in
a case of refractory ENL of 6-years duration [5]. From the
two available case reports on etanercept we emphasize that
etanercept can be an add-on drug with steroids/clofazimine/
thalidomide according to the situation.
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